Cannabinoids enhance human B‐cell growth at low nanomolar concentrations

FEBS Letters

Casellas, P.¹  Ségui, M.¹  Le Fur, G.¹  Derocq, J.-M.¹  Marchand, J.¹ 

[1] Department of Immunology, Sanofi Recherche, 371 rue du Professeur Blayac, 34184 Montpellier Cedex 04, France

关键词: Cannabinoid;    Immunomodulation;    B-Cell activation;    CP55;    940;    Δ-Tetrahydrocannabinol;    WIN55212-2;   

DOI  :  10.1016/0014-5793(95)00746-V

学科分类：生物化学/生物物理

来源: John Wiley & Sons Ltd.

【 摘 要 】

This study examined the effect of cannabinoid ligands on human tonsillar B-cells activated either through cross-linking of surface immunoglobulins or ligation of the CD40 antigen. The two synthetic cannabinoids, CP55,940 and WIN55212-2, as well as Δ⁹-tetrahydrocannabinol (THC), the psychoactive component of marijuana, caused a dose-dependent increase of B-cell proliferation and displayed EC₅₀ at low nanomolar concentrations. This cannabinoid-induced enhancing activity was inhibited by pertussis toxin which suggested a G-protein-coupled receptor process. In addition, the absence of antagonistic effect of SR141716A, a specific CB1 receptor antagonist, together with the demonstration that human B-cells displayed large amount of CB2 receptor mRNAs, led us to assume that the growth enhancing activity observed on B-cells at very low concentrations of cannabinoids could be mediated through the CB2 receptor.

【 授权许可】

Unknown